Sign in
Stories
Merck and Daiichi Sankyo Strike Cancer Drug Alliance, PharmaEssentia Enters License Agreement for Myeloid Immune Checkpoint Antibody Candidate
Share
Pharmaceutical Industry Enthusiastic Abo...
Advanced Ovarian Cancer Treatment Breakt...
Advancements in Antibodies to Protect Im...
Antibody Collaboration for Neurological ...
Overview
API
Merck and Daiichi Sankyo strike a cancer drug alliance, highlighting the pharmaceutical industry's interest in antibody-drug conjugates (ADCs). EpimAb Biotherapeutics and Almirall announce a license agreement to develop bispecific antibodies. I-Mab and ABL Bio provide updates on their PD-L1 and 4-1BB bispecific antibody candidate. PharmaEssentia enters into a license agreement for a myeloid immune checkpoint antibody candidate. The global biosimilar monoclonal antibodies market is projected to reach USD 65.42 billion by 2032.
Ask a question
How might the development of bispecific antibodies impact the pharmaceutical industry?
What are the key factors driving the growth of the biosimilar monoclonal antibodies market?
What are the potential benefits of antibody-drug conjugates (ADCs) in cancer treatment?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Apr 2023
Jun 2023
Aug 2023
Coverage